StockData
SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc. (SABS) stock

SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$3.20+0.25 (+8.47%)

Close on Nov 18, 2026Market cap $291.16MP/E –Yield –

SAB Biotherapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

SAB Biotherapeutics's total debt was $0 at Dec 31, 2024. For fiscal 2024 it was $0. The highest annual figure on record is $541.64K in fiscal 2022.

Annual total debt

PeriodPeriod endValueChange
FY2024Dec 31, 2024$0–
FY2023Dec 31, 2023$0-100.0%
FY2022Dec 31, 2022$541.64K–
FY2021Dec 31, 2021$0-100.0%
FY2020Dec 31, 2020$172.04K–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024$0–
Q4 FY2023Dec 31, 2023$0–
Q4 FY2022Dec 31, 2022$541.64K+214.8%
Q2 FY2022Jun 30, 2022$0–
Q1 FY2022Mar 31, 2022$0–
Q4 FY2021Dec 31, 2021$0–
Q4 FY2020Dec 31, 2020$172.04K–

More SAB Biotherapeutics figures

See a number that looks wrong?